NASDAQ: BPTHBio Path Holdings Inc Stock
$2.69-0.23 (-7.88%)
Updated Apr 23, 2024
BPTH Price
$2.69
Fair Value Price
$1.96
Market Cap
$1.82M
52 Week Low
$2.60
52 Week High
$44.80
P/E
-0.08x
P/B
4.13x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$16.08M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
6.3
Operating Cash Flow
-$12M
Beta
0.69
Next Earnings
May 10, 2024
Ex-Dividend
N/A
Next Dividend
N/A
BPTH Overview
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BPTH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BPTH ($2.69) is overvalued by 36.68% relative to our estimate of its Fair Value price of $1.96 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BPTH ($2.69) is not significantly undervalued (36.68%) relative to our estimate of its Fair Value price of $1.96 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BPTH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BPTH due diligence checks available for Premium users.
Be the first to know about important BPTH news, forecast changes, insider trades & much more!
BPTH News
Valuation
BPTH fair value
Fair Value of BPTH stock based on Discounted Cash Flow (DCF)
Price
$2.69
Fair Value
$1.96
Overvalued by
36.94%
BPTH ($2.69) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BPTH ($2.69) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BPTH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BPTH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.08x
Industry
16.46x
Market
41.92x
BPTH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.13x
Industry
5.93x
BPTH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BPTH's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.4M
Profit Margin
0%
BPTH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$3.2M
Liabilities
$2.8M
Debt to equity
6.3
BPTH's short-term assets ($3.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BPTH's short-term assets ($3.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BPTH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BPTH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.8M
Investing
$0.0
Financing
$514.0k
BPTH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BPTH vs Biotech Stocks
Bio Path Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.